Understanding how Treg cells adapt to cancer environments
A deubiquitination module controls Treg adaptation to tumor microenvironment
This study is looking at how certain immune cells called Treg cells change when they are in tumors, with the goal of finding ways to make cancer treatments work better for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10991826 on NIH RePORTER |
What this research studies
This research investigates how regulatory T (Treg) cells, which can suppress the immune response against tumors, adapt to the challenging conditions of the tumor microenvironment. The study focuses on identifying specific factors in the tumor environment that influence the function of Treg cells, particularly through a deubiquitinase module that affects a key protein called FoxP3. By exploring the role of USP21 and USP22 in Treg adaptation, the research aims to enhance the effectiveness of anti-tumor immunotherapy. Patients may benefit from insights that could lead to improved cancer treatments targeting Treg cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are undergoing or considering immunotherapy treatments.
Not a fit: Patients with non-cancerous conditions or those not receiving immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies by overcoming the immune suppression caused by Treg cells.
How similar studies have performed: Other research has shown promise in targeting Treg cells to enhance anti-tumor responses, indicating that this approach could be a valuable advancement in cancer treatment.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Fang, Deyu — Northwestern University at Chicago
- Study coordinator: Fang, Deyu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.